Importance of C-reactive protein in regulating monocyte tissue factor expression in patients with inflammatory rheumatic diseases

Journal of Rheumatology

Volumn 32, Issue 7, 2005, Pages 1224-1231

  Cai, Hong ^a   Song, Changjie ^a   Lim, Irwin Geok San ^b   Krilis, Steven A ^c   Geczy, Carolyn L ^a   McNeil, H Patrick ^a,d  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c ST GEORGE HOSPITAL   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

C reactive protein; Rheumatoid arthritis; Thromboplastin

Indexed keywords

BETA2 GLYCOPROTEIN 1; C REACTIVE PROTEIN; LIPOPOLYSACCHARIDE; MESSENGER RNA; THROMBOPLASTIN;

ADULT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; FEMALE; HUMAN; IN VITRO STUDY; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RHEUMATIC DISEASE; STATISTICAL SIGNIFICANCE; VASCULAR DISEASE;

ADULT; ARTERIOSCLEROSIS; ARTHRITIS, RHEUMATOID; BETA 2-GLYCOPROTEIN I; C-REACTIVE PROTEIN; CELLS, CULTURED; FEMALE; GLYCOPROTEINS; HUMANS; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; MONOCYTES; THROMBOPLASTIN; UP-REGULATION;

EID: 22244447061     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Cicala C, Cirino G. Linkage between inflammation and coagulation: an update on the molecular basis of the crosstalk. Life Sci 1998;62:1817-24.
2. Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation 2001;103:1718-20.
3. Jasani MK. Fibrin: metabolism, immunopathogenesis and significance in rheumatoid arthritis. In: Panayi GS, Johnson PM, editors. Immunopathogenesis of rheumatoid arthritis. Surrey: Red Books; 1978:137-46.
4. Zacharski LR, Brown FE, Memoli VA, et al. Pathways of coagulation activation in situ in rheumatoid synovial tissue. Clin Immunol Immunopathol 1992;63:155-62.
5. Busso N, Morard C, Salvi R, Peclat V, So A. Role of the tissue factor pathway in synovial inflammation. Arthritis Rheum 2003;48:651-9.
6. Petersen LC, Freskgard P, Ezban M. Tissue factor-dependent factor Vila signaling. Trends Cardiovasc Med 2000;10:47-52.
7. Esmon CT, Fukudome K, Mather T, et al. Inflammation, sepsis, and coagulation. Haematologica 1999;84:254-9.
8. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993;82:513-20.
9. Danenberg HD, Szalai AJ, Swaminathan RV, et al. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 2003;108:512-5.
10. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997;349:462-6.
11. Fichtischerer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000;102:1000-6.
12. Pasceri V, Yeh ET. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 1999;100:2124-6.
13. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
14. Ridker PM. On evolutionary biology, inflammation, infection, and the causes of atherosclerosis. Circulation 2002;105:2-4.
15. Libby P, Hansson K. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest 1991;64:5-14.
16. Marmur JD, Thiruvikraman SV, Fyfe BS, et al. Identification of active tissue factor in human coronary atheroma. Circulation 1996;94:1226-32.
17. Goodson N. Coronary artery disease and rheumatoid arthritis. Curr Opin Rheumatol 2002;14:115-20.
18. Bacon PA, Stevens RJ, Carruthers DM, Young SP, Kitas GD. Accelerated atherogenesis in autoimmune rheumatic diseases. Autoimmun Rev 2002;1:338-47.
19. Van Doornum S, McCoIl G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002;46:862-73.
20. Hahn BH. Systemic lupus erythematosus and accelerated atherosclerosis. New Engl J Med 2003;349:2379-80.
21. Sherer Y, Shoenfeld Y. Antiphospholipid syndrome, antiphospholipid antibodies, and atherosclerosis. Curr Atheroscler Rep 2001;3:328-33.
22. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990;87:4120-4.
23. Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;335:1544-7.
24. Amengual O, Atsumi T, Khamashta MA, Hughes GRV. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998;79:276-81.
25. Visvanathan S, McNeil HP. Cellular immunity to beta 2-glycoprotein-1 in patients with the antiphospholipid syndrome. J. Immunol 1999;162:6919-25.
26. Field SL, Brighton TA, McNeil HP, Chesterman CN. Recent insights into antiphospholipid antibody-mediated thrombosis. Baillieres Best Pract Clin Haematol 1999;12:407-22.
27. McNeil HP, Geczy CL, Harmer JA. Letter of retraction. "Monocyte tissue factor induction by activation of beta 2-glycoprotein-I-specific T lymphocytes is associated with thrombosis and fetal loss in patients with antiphospholipid antibodies", Journal of Immunology 2002;165:2258-62.
28. J Immunol 2002;169:1135.
29. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
30. Reddel SW, Wang YX, Sheng YH, Krilis SA. Epitope studies with anti-beta 2-glycoprotein 1 antibodies from autoantibody and immunized sources. J Autoimmun 2000;15:91-6.
31. Iverson GM, Reddel S, Victoria EJ, et al. Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol 2002;169:7097-103.
32. Geczy CL, Meyer PA. Leukocyte procoagulant activity in man: an in vitro correlate of delayed-type hypersensitivity. J Immunol 1982;128:331-6.
33. Walsh JD, Geczy CL. Discordant expression of tissue factor antigen and procoagulant activity on human monocytes activated with LPS and low dose cycloheximide. Thromb Haemost 1991;66:552-8.
34. Nakagomi A, Freedman SB, Geczy CL. Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex, and hormone replacement treatment. Circulation 2000;101:1785-91.
35. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
36. Hoffman M, Monroe DM, Roubey RA. Links between the immune and coagulation systems: how do "antiphospholipid antibodies" cause thrombosis? Immunol Res 2000;22:191-7.
37. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. New Engl J Med 1997;336:973-9.
38. Tracy RP, Lemaitre RN, Psaty BM, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997;17:1121-7.
39. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996;144:537-47.
40. Williams TN, Zhang CX, Game BA, He L, Huang Y. C-reactive protein stimulates MMP-1 expression in U937 histiocytes through FcγRII and extracellular signal-regulated kinase pathway: an implication of CRP involvement in plaque destabilization. Arterioscler Thromb Vasc Biol 2004;24:61-6.
41. Guha M, O'Connell MA, Pawlinski R, et al. Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor alpha expression by inducing Elk-1 phosphorylation and Egr-1 expression. Blood 2001;98:1429-39.